Lexicon Pharmaceuticals has an important data readout coming in the first quarter for a Phase IIb study testing pilavapadin, or LX9211, for diabetic peripheral neuropathic pain (DPNP). If that trial reads out positively, Lexicon will have more optionality because LX9211 is the company’s sole near-term clinical catalyst.
Lexicon Has A Lot Riding On LX9211 Phase IIb Readout In Pain
CEO Mike Exton talked to Scrip about moving the company forward after a disappointingly disruptive 2024.
